Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2015

The Pharma Closeout tracks 56 deals, $424.8B in disclosed deal value, 44 with a post-close Outcome Score for the year 2015.

Median Critic Score: 65  ·  Median Outcome Score: 48

Best outcome: Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) (91)  ·  Weakest outcome: Teva Pharmaceutical Industries Ltd. / Rimsa (8)

All 56 deals

• Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) — 2015 · $250M · Worked — the deal delivered on its rationale.
• Roche Holding AG / Foundation Medicine, Inc. — 2015 · $1.1B · Worked — the deal delivered on its rationale.
• Horizon Pharma plc / Crealta Holdings LLC — 2015 · $510M · Worked — the deal delivered on its rationale.
• Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals — 2015 · $3.5B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Acerta Pharma — 2015 · $4.0B · Worked — the deal delivered on its rationale.
• Celgene Corporation / Juno Therapeutics Inc. — 2015 · $2.0B · Worked — the deal delivered on its rationale.
• Vertex Pharmaceuticals Inc. / CRISPR Therapeutics AG — 2015 · $2.6B · Worked — the deal delivered on its rationale.
• Boston Scientific Corporation / Endo International plc (American Medical Systems Men's Health and Prostate Health) — 2015 · $1.6B · Worked — the deal delivered on its rationale.
• Zoetis Inc. / PHARMAQ Holding AS — 2015 · $765M · Worked — the deal delivered on its rationale.
• Boehringer Ingelheim International GmbH / Sanofi SA (Merial Animal Health) — 2015 · $12.4B · Worked — the deal delivered on its rationale.
• Horizon Pharma plc / Hyperion Therapeutics, Inc. — 2015 · $1.1B · Worked — the deal delivered on its rationale.
• AbbVie Inc. / Pharmacyclics Inc. — 2015 · $21.0B · Worked — the deal delivered on its rationale.
• Shire plc / NPS Pharmaceuticals — 2015 · $5.2B · Worked — the deal delivered on its rationale.
• Danaher Corporation / Pall Corporation — 2015 · $13.6B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / ZS Pharma Inc. — 2015 · $2.7B · Largely worked — most objectives met.
• Baxalta Incorporated / Sigma-Tau Finanziaria S.p.A. (Oncaspar portfolio) — 2015 · $900M · Largely worked — most objectives met.
• Celgene Corporation / Receptos Inc. — 2015 · $7.2B · Largely worked — most objectives met.
• Mylan Inc. / Theravance Biopharma, Inc. (TD-4208 program) — 2015 · $265M · Largely worked — most objectives met.
• Sanofi SA / Regeneron Pharmaceuticals, Inc. — 2015 · $2.2B · Mixed — partial payoff, real shortfalls.
• Mylan Inc. / Famy Care Limited (women's healthcare businesses) — 2015 · $800M · Mixed — partial payoff, real shortfalls.
• Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited — 2015 · $4.0B · Mixed — partial payoff, real shortfalls.
• Lupin Limited / Gavis Pharmaceuticals LLC and Novel Laboratories, Inc. — 2015 · $880M · Mixed — partial payoff, real shortfalls.
• Mallinckrodt plc / Therakos, Inc. — 2015 · $1.3B · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Lexicon Pharmaceuticals Inc. — 2015 · $1.7B · Underwhelmed — fell short of the thesis.
• AstraZeneca PLC / Takeda Pharmaceutical Company Limited (core respiratory business) — 2015 · $575M · Underwhelmed — fell short of the thesis.
• Astellas Pharma Inc. / Ocata Therapeutics, Inc. — 2015 · $379M · Underwhelmed — fell short of the thesis.
• Valeant Pharmaceuticals / Salix Pharmaceuticals — 2015 · $15.8B · Underwhelmed — fell short of the thesis.
• Mallinckrodt plc / Ikaria, Inc. — 2015 · $2.3B · Underwhelmed — fell short of the thesis.
• Alexion Pharmaceuticals Inc. / Synageva BioPharma — 2015 · $8.4B · Underwhelmed — fell short of the thesis.
• Allergan plc / Oculeve, Inc. — 2015 · $250M · Underwhelmed — fell short of the thesis.
• Lannett Company, Inc. / UCB S.A. (Kremers Urban Pharmaceuticals Inc.) — 2015 · $1.2B · Underwhelmed — fell short of the thesis.
• Pfizer Inc. / Allergan, Inc. — 2015 · $160.0B · Did not work — the deal failed to deliver.
• Hikma Pharmaceuticals PLC / Boehringer Ingelheim (Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc.) — 2015 · $2.6B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Flexus Biosciences, Inc. — 2015 · $1.2B · Did not work — the deal failed to deliver.
• Allergan plc / Kythera Biopharmaceuticals, Inc. — 2015 · $2.1B · Did not work — the deal failed to deliver.
• Teva Pharmaceutical Industries Ltd. / Allergan plc (Generics Business) — 2015 · $40.5B · Did not work — the deal failed to deliver.
• Pfizer Inc. and Les Laboratoires Servier / Cellectis SA (UCART19 program) — 2015 · $338M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Cardioxyl Pharmaceuticals, Inc. — 2015 · $2.1B · Did not work — the deal failed to deliver.
• Merck & Co., Inc. / cCAM Biotherapeutics Ltd. — 2015 · $605M · Did not work — the deal failed to deliver.
• Concordia Healthcare Corp. / Amdipharm Mercury Limited (AMCo) — 2015 · $3.5B · Did not work — the deal failed to deliver.
• Novartis AG / Spinifex Pharmaceuticals, Inc. — 2015 · $700M · Did not work — the deal failed to deliver.
• Endo International plc / Par Pharmaceutical Holdings, Inc. — 2015 · $8.1B · Did not work — the deal failed to deliver.
• Allergan plc / Naurex, Inc. — 2015 · $560M · Did not work — the deal failed to deliver.
• Teva Pharmaceutical Industries Ltd. / Rimsa — 2015 · $2.3B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Promedior, Inc. — 2015 · $1.2B
• Teva Pharmaceutical Industries Ltd. / Mylan N.V. — 2015 · $40.0B
• Eli Lilly and Company / Hanmi Pharmaceutical Co., Ltd. (HM71224 program) — 2015 · $690M
• Amgen Inc. / Dezima Pharma B.V. — 2015 · $1.6B
• AbbVie Inc. / Halozyme Therapeutics, Inc. (ENHANZE platform) — 2015 · $1.2B
• Novartis AG / Aduro Biotech, Inc. (STING pathway program) — 2015 · $750M
• Bristol-Myers Squibb Company / Bavarian Nordic A/S (PROSTVAC program) — 2015 · $975M
• Bristol-Myers Squibb Company / Five Prime Therapeutics, Inc. (CSF1R antibody program) — 2015 · $1.7B
• Boehringer Ingelheim International GmbH / Hanmi Pharmaceutical Co., Ltd. (HM61713 program) — 2015 · $730M
• Amgen Inc. / Kite Pharma, Inc. — 2015 · $585M
• Mylan N.V. / Perrigo Company plc — 2015 · $26.0B
• Sanofi SA / Hanmi Pharmaceutical Co., Ltd. (Quantum Project) — 2015 · $4.2B

← Deal Library  ·  Interactive search  ·  How we score deals